Amaryl®М SR: a New Release Form, New Possibilities for The Patients

Огляд присвячений новій формі пероральних антидіабетичних препаратів із фіксованою дозою — комбінації метформіну сповільненого вивільнення та глімепіриду. Амарил®М СР (2/500 мг) — нова лікарська форма, що забезпечує швидке вивільнення глімепіриду, а потім повільне вивільнення метформіну з мультиполімерного гідрофільного матриксу незалежно від рН. На підставі дослідження терапевтичної ефективності та біодоступності показано, що ця форма характеризується оптимальною фармакокінетикою метформіну та глімепіриду, не призводить до збільшення частоти гіпоглікемій, може призначатися одноразово на добу й асоційована з меншою вираженістю шлунково-кишкових побічних ефектів, а також із більшою прихильністю до лікування. Застосування Амарилу®М СР створює нові можливості для хворих на цукровий діабет 2-го типу щодо оптимізації глікемічного контролю та якості життя.

• Publication year

  2015

• Venue

  International Journal of Endocrinology

• Publication date

  2015-11-24

• Fields of study

  Not labeled

• Identifiers
  DOI 10.22141/2224-0721.5.69.2015.75095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report

  2014cited by this paper
• Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!

  2014cited by this paper
• Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea

  2014cited by this paper
• Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis

  2013cited by this paper
• Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia

  2013cited by this paper
• Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination.

  2012cited by this paper
• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

  2011cited by this paper
• Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover

  2011cited by this paper
• Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers.

  2010cited by this paper
• Glimepiride upregulates eNOS activity and inhibits cytokine‐induced NF‐κB activation through a phosphoinoside 3‐kinase–Akt‐dependent pathway

  2009cited by this paper
• Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.

  2009cited by this paper
• Oral antidiabetic medication adherence and glycemic control in managed care.

  2008cited by this paper
• Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHP

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

  2007cited by this paper
• Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents

  2007cited by this paper
• Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial

  2006cited by this paper
• Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis.

  2006cited by this paper
• Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

  2006cited by this paper
• Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation

  2005cited by this paper
• Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

  2004cited by this paper
• The role of glimepiride in the effective management of Type 2 diabetes.

  2004cited by this paper
• A Systematic Review of Adherence With Medications for Diabetes

  2004cited by this paper
• Impairment of myocardial protection in type 2 diabetic patients.

  2003cited by this paper
• Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes

  2003cited by this paper
• Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study

  2003cited by this paper
• Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy.

  2002cited by this paper
• Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study

  2002cited by this paper
• Patient Compliance and Persistence with Anti-Hyperglycemic Therapy: Evaluation of a Population of Type 2 Diabetic Patients

  2002cited by this paper
• Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients

  2001cited by this paper
• Pharmacokinetics of Metformin Gastric‐Retentive Tablets in Healthy Volunteers

  2001cited by this paper
• Pharmacokinetics and Bioavailability of a Metformin/Glyburide Tablet Administered Alone and with Food

  2000cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

  1996cited by this paper
• Kidney Function and Age Are Both Predictors of Pharmacokinetics of Metformin

  1995cited by this paper
• Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study

  1994cited by this paper
• Methodological Issues in Diabetes Research: Measuring adherence

  1992cited by this paper
• KINETIC STUDY OF NORMAL AND SUSTAINED RELEASE DOSAGE FORMS OF METFORMIN IN NORMAL SUBJECTS

  1980cited by this paper

• No citing papers are available for this paper.